Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gimsilumab - Eisai Inc/Roivant Sciences

Drug Profile

Gimsilumab - Eisai Inc/Roivant Sciences

Alternative Names: KIN-1901; MORAb 022

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Morphotek
  • Developer Eisai Inc; Kinevant Sciences GmbH; Ludwig Institute for Cancer Research; Morphotek; Roivant Sciences
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ankylosing spondylitis; SARS-CoV-2 acute respiratory disease
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 28 Dec 2022 No development reported - Phase-II for SARS-COV-2 acute respiratory disease in USA (IV)
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Ankylosing-spondylitis in Canada (SC, Injection)
  • 13 Dec 2021 Efficacy data from the phase II BREATHE trial presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top